Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-04-14 Governance Information
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
承诺管理制度
Governance Information Classification · 95% confidence The document is titled '承诺管理制度' (Commitment Management System) and details the company's internal policy regarding commitments made by the company, its controlling shareholders, directors, and other related parties. It includes procedural rules, disclosure requirements, and governance related to these commitments. The document is a formal announcement of a governance policy passed by the board of directors on April 11, 2024, and does not contain financial statements, audit results, or earnings data. It is not a report of financial performance or a regulatory filing about financial results. It is also not a proxy statement or voting result announcement. The content is focused on governance and internal management rules, which aligns best with Governance Information (CGR). The document length is 2390 characters, which is relatively short but contains substantive governance content rather than a mere announcement or certification. Therefore, the classification is Governance Information (CGR).
2024-04-14 Chinese
董事会审计委员会工作细则
Governance Information Classification · 95% confidence The document is titled "北京三元基因药业股份有限公司 董事会审计委员会工作细则" which translates to "Beijing Sanyuan Gene Pharmaceutical Co., Ltd. Board Audit Committee Working Rules." It details the composition, responsibilities, meeting rules, and procedures of the Audit Committee of the Board of Directors. There is no financial data, no financial results, no earnings information, no voting results, no legal proceedings, no capital changes, no merger or acquisition information, and no report publication announcement. The document is a governance-related internal rules document about the audit committee's operation and oversight functions. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3320 characters, which is not very short but contains detailed governance rules. Therefore, the classification is CGR with high confidence.
2024-04-14 Chinese
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an annual report summary from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It contains detailed company information, business overview, financial data for the year 2023, shareholder structure, and notes on assets and liabilities. It references the full annual report and includes audited financial data with an unqualified audit opinion from Zhongshen Hua Certified Public Accountants. The document length is over 10,000 characters, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an official yearly report covering company activity and full financial performance, consistent with an Annual Report (10-K) filing type. FY 2023
2024-04-14 Chinese
关于部分募集资金投资项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the delay of certain projects funded by previously raised capital. It details the background of the fundraising, the use of funds, the reasons for the delay, and the approvals from the board, supervisory committee, independent directors, and the sponsor institution. The document does not contain financial statements or detailed financial performance data but focuses on the status and management of the use of raised funds. It is a regulatory announcement about the status of capital use and project progress, specifically about the postponement of investment projects funded by raised capital. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is under 5,000 characters, but it is not merely announcing the publication of a report; it provides substantive information about the capital use and project delays. Therefore, the best classification is CAP with high confidence.
2024-04-14 Chinese
拟续聘2024年度会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm for the 2024 fiscal year. It details the background, qualifications, and audit fees of the accounting firm, as well as the board and audit committee's approval process. It does not contain any actual financial statements or audit reports, but rather is a formal notice about the appointment of the auditor. The document length is under 5,000 characters and it is clearly an announcement rather than a full audit report or annual report. Therefore, it fits best under the category of Audit Report / Information announcements, specifically about auditor appointment, which aligns with the Audit Report / Information (AR) category rather than a full audit report or annual report. FY 2024
2024-04-14 Chinese
审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report from the Audit Committee regarding the supervision of the accounting firm for the 2023 fiscal year. It discusses the evaluation and oversight of the auditor's performance, qualifications, and independence in relation to the company's 2023 annual audit. The document references the 2023 annual report audit work but does not contain the actual audited financial statements or detailed financial data itself. It is a standalone report on audit supervision and evaluation, not the full annual report or audit report. The document length is 1755 characters, which is relatively short and consistent with a supervisory or evaluation report rather than a full audit report. Therefore, this fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related supervisory information, excluding full annual reports. FY 2023
2024-04-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.